Richard Lindstrom, MD
Leadership Richard Lindstrom, MD Founder & Chairman Dr. Richard Lindstrom is a founder, director and has been an attending surgeon at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. Dr. Lindstrom has served as a researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon in the ophthalmology field. He has also served as a member of the board of directors of TearLab Corporation since 2010 and Ocular Therapeutix, Inc. since 2012. Dr. Lindstrom has also served as associate director of the Minnesota Lions Eye Bank since 1987 and he is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several other privately-held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery from 1993 to 1994, the International Intraocular Implant Society from 2002 to 2004, the International Refractive Surgery Club from 2002 to 2004, and the American Society of Cataract and Refractive Surgery from 2007 to 2008. Dr. Lindstrom currently serves on the ASCRS Executive Committee and is a board member of the ASCRS Foundation. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently an adjunct professor emeritus. Dr. Lindstrom is also a board member of the University of Minnesota Foundation, chairing the Ophthalmology and Visual Neurosciences Division. Dr. Lindstrom holds a B.A. degree in Pre-Medical Studies, a B.S. degree in Medicine and an M.D. degree from the University of Minnesota. Dr. Lindstrom brings to the Board over 30 years of ophthalmology industry experience, as well extensive experience serving as a director of other companies. Back to Leadership Page
J. Andy Corley
Leadership J. Andy Corley Director Mr. Corley has a 45 + year history in the eye care industry. Starting his career at Allergan in 1978 as a sales representative, his career has centered on the commercial aspects of ophthalmic technology. In 1984 he joined American Medical Optics and participated in the launch of the YAG laser, later that decade he was a co-founder of Chiron Vision. As General Manager of Chiron Vision’s Refractive Surgery Division, He and his teammates introduced the Casebeer RK courses. The company trained over 6000 US surgeons in RK surgery, introducing most of them to their first private surgical pay effort. Using that experience, the same team launched the LASIK procedure andprivate surgical pay became a permanent and meaningful part of the ophthalmicsurgeon’s armamentarium. As the CEO of eyeonics, he led the creation of the premium channel for cataract surgery which became reality in May of 2005. As aresult of his efforts at eyeonics, he was the Orange County Entrepreneur of the Year in 2005. He served as the President of Bausch & Lomb Surgical Division from 2008 to 2011. In 2011 Mr. Corley formed Yelroc Consulting Inc. focusing on all aspects of company building with an emphasis on high performance management process. In 2015 he co-founded the Flying L Investment Partnership focusing on ophthalmic innovation. In 2020 he co-founded the Loving Eyes Foundation to create custom-fit glasses for children with unique facial anatomy. He currently serves on the boards of numerous ophthalmic device and pharmaceutical companies, including Chairman of the Board of RXST, Belkin Vision, and Neurolens. In his spare time he enjoys his grandchildren and golf with colleagues. Mr. Corley attended Georgia Southern University. Awards include: Lindstrom Leadership Award 2024, AECOS Visionary Award Winner 2022, Inaugural Ophthalmology Innovation Summit Innovation Award 2009, Foundation for Fighting Blindness Visionary Award 2011, and AECOS Dave Dulaney Award 2010. Back to Leadership Page
Adrienne Graves, PhD
Leadership Adrienne Graves, PhD Lead Director Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. Dr. Graves was CEO of Santen Inc (2002-2010) following 7 years there as Sr VP of Worldwide Clinical Development. She previously spent 9 years at Alcon, where she built a Retinal Electrophysiology Lab, directed clinical development and served as Director of International Ophthalmology. Dr. Graves was Chairman of the Board at Iveric Bio until their 2023 acquisition by Astellas, and is also currently on the Board of Directors at Harrow, Qlaris Bio, Ocular Therapeutix, Opus Genetics, NVasc, JelliSee, and Implandata. She previously held board positions at Encore Vision (acquired by Novartis), Envisia (assets acquired by Aerie), TearLab (now Trukera), Aerpio, and Akorn. Dr. Graves also serves on the boards of the following Foundations: American Society of Cataract and Refractive Surgeons (ASCRS), Glaucoma Research Foundation (GRF), American Academy of Ophthalmology (AAO; Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB), and was a founding board member of OWL (Ophthalmic World Leaders). She is Chairman of the RD (Retinal Degeneration) Fund, the venture arm of FFB, and she Co-founded Glaucoma 360. Her recent honors include the Visionary Award (FFB), Catalyst Award (GRF), Visionary Award (OWL), Bernice Brown Memorial Lecture Award (WIO), and The Ophthalmologist 2021 and 2023 Power Lists. Dr. Graves received an AB with Honors in Psychology from Brown University, a Ph.D. in Pyschobiology from the University of Michigan, and a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris. She is a Visionary Innovation Mentor for the Ophthalmic Innovation Program at Stanford. Back to Leadership Page
Perry J. Sternberg
Leadership Perry J. Sternberg Director Perry Sternberg, who currently serves as President and Chief Executive Officer for Corium, Inc., brings more than 25 years of experience in the biotechnology and pharmaceutical industries, with commercial experience across a wide range of therapeutic areas, including ophthalmics, in diverse markets. Sternberg spent time working with therapies for both the anterior and posterior segments of the eye while at Novartis Ophthalmics, Bausch + Lomb, and, most recently, Shire. At Shire, one of his areas of responsibility was establishing the Global Ophthalmics Business Unit and bringing Xiidra® to the U.S. Market. During the course of his career, he has had direct responsibility for launch and commercialization of more than twenty products. Hallmarks of Mr. Sternberg’s business style and success are his unrelenting focus on exceeding the needs of customers and bringing out the optimal performance in his teams.He holds a bachelor’s degree in Animal Bioscience from Pennsylvania State University. Back to Leadership Page
Shelley Thunen
Leadership Shelley Thunen Director Shelley Thunen joined as a member of our board of directors and chair of the audit committee in August 2020. Since January 2016, Ms. Thunen has served as the Chief Financial Officer of RxSight, Inc., a publicly held company (Nasdaq:RXST), that developed and markets the world’s only adjustable intraocular lens for cataract surgery. Prior to joining RxSight, Ms. Thunen has held financial and operations leadership roles in several medical device and vision care companies, including Endologix, Inc., LenSx, Inc., and IntraLase Corp. In these roles, she advanced companies responsible for innovations in eye care such as the first femtosecond laser for cataract surgery (LenSx) and the first femtosecond laser to create the corneal flap as the first step to LASIK surgery (IntraLase). Prior Board of Directors and audit chair experience includes: Restoration Robotics, Inc., a publicly held company, acquired in 2019; LenSx Lasers, Inc., acquired in 2010; and eyeonics, Inc. acquired in 2008. Ms. Thunen received a B.A. in economics and an M.B.A. from the University of California, Irvine. Additional Board of Director positions include: AEON Biopharma, Inc. (NYSE:AEON) and LENZ Pharmaceuticals, Inc. Back to Leadership Page